Loading...
Market
Xaira's market position by end of 2025
4
Resolution / Starting Odds
Leader in biotech market • 25%
Top 5 in biotech market • 25%
Moderately successful • 25%
Struggles to scale • 25%
Market analysis reports and company financial statements
Story
Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech
Apr 25, 2024, 12:25 AM
Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.
View original story
Similar markets
Under $30 billion • 25%
$30 billion to $50 billion • 25%
$50 billion to $70 billion • 25%
Over $70 billion • 25%
Under $30 billion • 25%
$30 billion to $50 billion • 25%
$50 billion to $70 billion • 25%
Over $70 billion • 25%
Top 10 globally • 25%
Top 50 globally • 25%
No significant change • 25%
Loses market position • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Outside Top 20 • 25%
No significant change • 33%
Increase in market share • 33%
Decrease in market share • 33%
Healthcare • 20%
Automotive • 20%
Finance • 20%
Retail • 20%
Energy • 20%
Highly successful • 33%
Moderately successful • 34%
Unsuccessful • 33%
Significant growth (>15% increase) • 33%
Moderate growth (5-15% increase) • 34%
No significant change (<5% increase or decrease) • 33%